<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146112">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01668186</url>
  </required_header>
  <id_info>
    <org_study_id>11-090-PED</org_study_id>
    <nct_id>NCT01668186</nct_id>
  </id_info>
  <brief_title>Longitudinal Natural History Study of Patients With Peroxisome Biogenesis Disorders (PBD)</brief_title>
  <official_title>Longitudinal Natural History Study of Patients With Peroxisome Biogenesis Disorders (PBD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nancy Braverman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Center</source>
  <oversight_info>
    <authority>Canada: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Peroxisome Biogenesis Disorders (PBD) are a group of inherited disorders due to defects
      in peroxisome assembly causing complex developmental and metabolic sequelae. In spite of
      advancements in peroxisome biology, the pathophysiology remains unknown, the spectrum of
      phenotypes poorly characterized and the natural history not yet systematically reported. Our
      aims are to further define this population clinically, biochemically and genetically. The
      investigators will prospectively follow patients from Canada, the US and internationally,
      and collect data from medical evaluations, blood, urine and imaging studies that would be
      performed on a clinical care basis. Patients unable to attend clinics can participate in
      this study by mailing in their medical information. The investigators will use this
      information to identify standards of care and improve management.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Documentation of the clinical findings</measure>
    <time_frame>yearly up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical findings include life span, growth, development, vision, hearing, neurological examinations, renal problems, adrenal problems skeletal problems and any other system involvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peroxisome function testing</measure>
    <time_frame>yearly up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To include very long chain saturated, branched and polyunsaturated fatty acids, bile acids, plasmalogens, pipecolic acid, adrenal functions, liver functions, urine oxalate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of PEX gene mutations</measure>
    <time_frame>once</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of leukodystrophy</measure>
    <time_frame>yearly up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Identification of patterns and course by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scoring of fundus photography</measure>
    <time_frame>yearly up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Identification of patterns and course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of phenotype with genotype</measure>
    <time_frame>yearly up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency in the population of various disease complications</measure>
    <time_frame>yearly up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Peroxisome Biogenesis Disorders</condition>
  <arm_group>
    <arm_group_label>Patients diagnosed with PBD</arm_group_label>
    <description>Patients diagnosed with PBD</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient with a PBD diagnosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of PBD or

          -  Single peroxisome enzyme defect with phenotype similar to PBD

        Exclusion Criteria:

          -  Not a PBD

          -  Not a single peroxisome enzyme defect with phenotype similar to PBD
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy E Braverman, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Center, Montreal Childrens Hopital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nancy E Braverman, MD, MS</last_name>
    <phone>(1) 514-934-1934</phone>
    <phone_ext>23404</phone_ext>
    <email>nancy.braverman@mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francois Plourde, MSc, MSc</last_name>
    <phone>(1) 514-934-1934</phone>
    <phone_ext>23403</phone_ext>
    <email>francois.plourde@mail.mcgill.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montreal Childrens Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z 2Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nancy E Braverman, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Steinberg SJ, Raymond GV, Braverman NE, Moser AB. Peroxisome Biogenesis Disorders, Zellweger Syndrome Spectrum. 2003 Dec 12 [updated 2012 May 10]. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from http://www.ncbi.nlm.nih.gov/books/NBK1448/</citation>
    <PMID>20301621</PMID>
  </reference>
  <reference>
    <citation>Braverman NE, Moser AB, Steinberg SJ. Rhizomelic Chondrodysplasia Punctata Type 1. 2001 Nov 16 [updated 2012 Sep 13]. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from http://www.ncbi.nlm.nih.gov/books/NBK1270/</citation>
    <PMID>20301447</PMID>
  </reference>
  <reference>
    <citation>Steinberg SJ, Dodt G, Raymond GV, Braverman NE, Moser AB, Moser HW. Peroxisome biogenesis disorders. Biochim Biophys Acta. 2006 Dec;1763(12):1733-48. Epub 2006 Sep 14. Review.</citation>
    <PMID>17055079</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 8, 2013</lastchanged_date>
  <firstreceived_date>August 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Center</investigator_affiliation>
    <investigator_full_name>Nancy Braverman</investigator_full_name>
    <investigator_title>MD, M.Sc. Associate Professor, Depts. of Human Genetics and Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Peroxisome biogenesis disorders</keyword>
  <keyword>PBD</keyword>
  <keyword>Zellweger spectrum</keyword>
  <keyword>Rhizomelic chondrodysplasia punctata</keyword>
  <keyword>RCDP</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peroxisomal Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
